Stocks-BPMC-Blueprint Medicines Corp

BPMC Blueprint Medicines Corp

88.90 4.80 (5.71%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Stocks-BPMC-Blueprint Medicines Corp
BPMC Blueprint Medicines Corp
Trade

Blueprint Medicines Corp price

-1.93% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
5.33B
Day’s Range
84.28
-
88.78
52W Range
43.82
-
121.49
Volume (3M)
677.89K
Price-Earnings Ratio
-24.57
Revenue
362.8M
Top Discussions
orbitalnewt
Hungary
about a month ago
$MED.US (Medifast Inc) $MPW (Medical Properties Trust Inc) $BPMC (Blueprint Medicines Corp) $NSDQ100 $O (Realty Income Corp) @EquityFund
EquityFund
Hungary
about a month ago
💡Instead of the overhyped $NVDA (NVIDIA Corporation) and $MSFT (Microsoft) here is an interesting Investment Case for Medifast ( $MED.US (Medifast Inc) ) (Q2 REPORT 5th of AUG)!!! 📉As of now, Medifast has witnessed a tremendous drop in the stock price from $330 (May 2021) to around $20 (now) 🔍They... Show More Translate
Like CommentShare
2 of 3
null
.
ForbiSK
Germany
4 months ago
Update for Followers and Our Copier 🚀 Hello everyone, As announced earlier, we are making our portfolio more focused on growth while maintaining diversity across sectors and US and EU markets. Here are the latest updates: 💼 Closed Trades with Profit: 🏎️ $RACE (Ferrari NV): 5.11% profit 💊 $VRTX... Show More
Like CommentShare
ForbiSK
Germany
4 months ago
Top3 performers of our portfolio: $AMZN (Amazon.com Inc) - up 21%. Tech/retail sector. $RHM.DE (Rheinmetall AG) - up 19%. Defence/Military sector. $BPMC (Blueprint Medicines Corp) - up 17%. Biotech/Medicine sector. A testament to diversification and core sectors we are invested in. - Perfect time... Show More
Like CommentShare
Gio84gio
Italy
4 months ago
♦️ Aggiornamento Portafoglio ♦️ 🟩RENDIMENTO DA INIZIO ANNO : 11,79% 🟩RENDIMENTO A DUE ANNI : 29,02% 🟩PUNTEGGIO DI RISCHIO: 5 🟩SETTIMANE IN PROFITTO : 81.25 % 🟩COPIATORI: 12📈 🟩FOLLOWER: 93📈 🔸Cari Copiatori e Follower, buono l'inizio di maggio con un +1,19% di ieri e un +1,91% della giornata... Show More Translate
Like CommentShare
2 of 6
1 reply
null
.
ForbiSK
Germany
4 months ago
Promising start of May: yesterday 0.71% up, today 2.3% up so far, $BPMC (Blueprint Medicines Corp) and $RXRX (Recursion Pharmaceuticals Inc) leading the way.
Like CommentShare
null
.
ForbiSK
@ForbiSK shared a post via @ForbiSK
Germany
7 months ago
Investing in $VRTX (Vertex Pharmaceuticals Incorporated) , $BPMC (Blueprint Medicines Corp) (healthcare/biotech), $AMD (Advanced Micro Devices Inc) , $TSLA (Tesla Motors, Inc.) (tech/AI) and more. Defence/military sector in sight. Follow for updates.
ForbiSK
Germany
7 months ago
So: My portfolio is up 21.01% in the past month. We have Portfolio with investments in less volatile and growth potential having companies, across different areas like health-care/biotech sector, tech/AI sector and now military/defence sector in sight, which faces multiple growth opportunities with... Show More Translate
Like CommentShare
null
.
ForbiSK
Germany
7 months ago
🟢4.2% up last week. 🟢20.5% up in February. 🟢Last week made some changes to portfilio: Closed $SMCI (Super Micro Computer, Inc) with 151% profit and redistributed capital to more diversified areas like healthcare/biotech and F1: opened positions in $VRTX (Vertex Pharmaceuticals Incorporated), $BPMC... Show More
Like CommentShare
MarketUpdates
United Kingdom
7 months ago
$BPMC (Blueprint Medicines Corp) Q1 2024 earnings report is expected to be released
2
MAY
Reports
Q1, 2024 earnings report expected
BPMC
BPMC
Blueprint Medicines Corp
88.90
4.80
(5.71%)
Trade
Like CommentShare
MarketUpdates
United Kingdom
7 months ago
$BPMC (Blueprint Medicines Corp) Q1 2024 earnings report is expected to be released
2
MAY
Reports
Q1, 2024 earnings report expected
BPMC
BPMC
Blueprint Medicines Corp
88.90
4.80
(5.71%)
Trade
Like CommentShare

About Blueprint Medicines Corp

Blueprint Medicines Corp is an American pharmaceutical and medical manufacturing company based in Cambridge, Massachusetts. Established in 2008, the firm focuses on the identification of kinases that act as drivers of genomically defined cancers and hematologic disorders. Operating globally, the firm uses its research to develop precision therapies that aim to provide significant clinical responses in patients and greatly increase quality of life. The firm’s products include AYVAKIT/AYVAKYT (avapritinib), which is used for the treatment of a rare hematologic disorder called systemic mastocytosis (SM), characterised by the production of excess mast cells leading to the accumulation of mast cells in the bone marrow and other organs. Blueprint also produces GAVRETO (pralsetinib), an oral therapy for patients with RET-positive metastatic non-small lung cancer and advanced thyroid cancer. The company has a number of products in the pipeline at various clinical and pre-clinical phases, primarily focused on improving outcomes for patients living with genomically defined cancers, advanced cancers, and hematologic disorders. The firm worked in collaboration with Genentech, a member of the Roche Group, to develop and commercialise pralsetinib as a therapy for patients with RET-altered cancers. Blueprint Medicines Corp is listed on the NASDAQ, where it trades under the stock ticker BPMC. Learn more about the performance of BPMC share prices on eToro.
Kathryn Haviland, MBA
CEO
655
Employees
2008
Founded
Cambridge, Massachusetts, US
HQ
Show More
Med TechNASDAQ

ESG: A New Source of Insight

What is an ESG Score?
This number is a measure of a company’s exposure to environmental, social, and governance risks. Influencing factors include energy efficiency, safety, social policies, and more. Learn More
Powered by ESG Book
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
53
Medium
Industry 
Avg. 43 
40
Environment
58
Social
48
Governance

Analyst Forecast

Consensus
Strong Buy
Price Target
130.67
Based on 5 analysts who covered BPMC 

People Also Bought

BPMC Upcoming events

24
OCT
Earnings Report
Q4 2024
Before Market Open